Following validation of Myriad’s myChoice® CDx in the randomised, Phase 3 trial, PAOLA-1 reporting that patients with HRD-positive tumours had longer median progression-free survival and overall survival with first-line bevacizumab and olaparib therapy [10,29]; this commercial assay has been adopted by many cancer centres to detect tumour BRCA1/2 pathogenic variants [30,31]. Here, BRCA1 is linked to neoplasm.